Axsome Therapeutics’ (AXSM) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a report issued on Tuesday morning, Benzinga reports. The firm currently has a $190.00 price objective on the stock. HC Wainwright also issued estimates for Axsome Therapeutics’ Q3 2025 earnings at $0.47 EPS and Q4 2025 earnings at $1.33 EPS.

A number of other research analysts also recently issued reports on the company. Royal Bank of Canada upped their price objective on Axsome Therapeutics from $123.00 to $128.00 and gave the company an outperform rating in a research note on Tuesday, March 26th. Morgan Stanley raised shares of Axsome Therapeutics from an equal weight rating to an overweight rating and increased their target price for the company from $90.00 to $115.00 in a research report on Monday, April 29th. Mizuho increased their price target on Axsome Therapeutics from $108.00 to $109.00 and gave the stock a buy rating in a research note on Thursday, March 28th. Cantor Fitzgerald reiterated an overweight rating and issued a $107.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, April 10th. Finally, Piper Sandler upped their price target on shares of Axsome Therapeutics from $90.00 to $113.00 and gave the company an overweight rating in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $121.92.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $73.68 on Tuesday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.52 and a current ratio of 3.63. The firm’s 50-day simple moving average is $73.84 and its 200 day simple moving average is $75.72. The stock has a market cap of $3.50 billion, a price-to-earnings ratio of -11.55 and a beta of 1.13. Axsome Therapeutics has a fifty-two week low of $55.02 and a fifty-two week high of $98.40.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Tuesday, February 20th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.48. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%. The business had revenue of $71.53 million during the quarter, compared to analyst estimates of $70.38 million. As a group, research analysts anticipate that Axsome Therapeutics will post -3.75 earnings per share for the current fiscal year.

Insider Transactions at Axsome Therapeutics

In other news, Director Roger Jeffs sold 29,976 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $69.70, for a total value of $2,089,327.20. Following the completion of the sale, the director now owns 120,756 shares of the company’s stock, valued at approximately $8,416,693.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Roger Jeffs sold 29,976 shares of Axsome Therapeutics stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total value of $2,089,327.20. Following the transaction, the director now owns 120,756 shares of the company’s stock, valued at approximately $8,416,693.20. The disclosure for this sale can be found here. 24.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Axsome Therapeutics

Several large investors have recently modified their holdings of the stock. Perceptive Advisors LLC increased its stake in Axsome Therapeutics by 115.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,038,019 shares of the company’s stock valued at $82,616,000 after purchasing an additional 556,370 shares in the last quarter. Eventide Asset Management LLC bought a new stake in Axsome Therapeutics in the 3rd quarter worth approximately $24,232,000. Point72 Asset Management L.P. increased its position in Axsome Therapeutics by 57.4% during the fourth quarter. Point72 Asset Management L.P. now owns 837,201 shares of the company’s stock valued at $66,633,000 after acquiring an additional 305,264 shares during the last quarter. First Turn Management LLC purchased a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $23,513,000. Finally, RTW Investments LP increased its holdings in Axsome Therapeutics by 4.8% during the third quarter. RTW Investments LP now owns 4,489,596 shares of the company’s stock valued at $313,778,000 after buying an additional 205,319 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.